SpectraCure AB (publ) (SPEC.ST)
SEK 3.59
(15.81%)
SEK 3.59
(15.81%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 14.97 Million SEK | 23.56% |
| 2022 | 12.12 Million SEK | -18.33% |
| 2021 | 14.84 Million SEK | 11.42% |
| 2020 | 13.32 Million SEK | 7.31% |
| 2019 | 12.41 Million SEK | 208.01% |
| 2018 | 4.03 Million SEK | 209.74% |
| 2017 | 1.3 Million SEK | -80.46% |
| 2016 | 6.65 Million SEK | 542.83% |
| 2015 | 1.03 Million SEK | -88.04% |
| 2014 | 8.66 Million SEK | 269.23% |
| 2013 | 2.34 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 17.41 Million SEK | 16.29% |
| 2024 Q2 | 14.03 Million SEK | -19.38% |
| 2023 Q1 | 12.23 Million SEK | 0.95% |
| 2023 FY | 14.97 Million SEK | 23.56% |
| 2023 Q4 | 14.97 Million SEK | 3.07% |
| 2023 Q3 | 14.52 Million SEK | -2.93% |
| 2023 Q2 | 14.96 Million SEK | 22.33% |
| 2022 Q1 | 15.6 Million SEK | 5.12% |
| 2022 FY | 12.12 Million SEK | -18.33% |
| 2022 Q4 | 12.12 Million SEK | 0.73% |
| 2022 Q3 | 12.03 Million SEK | -10.07% |
| 2022 Q2 | 13.38 Million SEK | -14.24% |
| 2021 FY | 14.84 Million SEK | 11.42% |
| 2021 Q1 | 17.84 Million SEK | 33.98% |
| 2021 Q2 | 15.68 Million SEK | -12.13% |
| 2021 Q3 | 15.67 Million SEK | -0.07% |
| 2021 Q4 | 14.84 Million SEK | -5.3% |
| 2020 Q1 | 14.12 Million SEK | 13.82% |
| 2020 Q2 | 27.98 Million SEK | 98.07% |
| 2020 Q3 | 11.15 Million SEK | -60.15% |
| 2020 Q4 | 13.32 Million SEK | 19.45% |
| 2020 FY | 13.32 Million SEK | 7.31% |
| 2019 Q2 | 15.65 Million SEK | 146.02% |
| 2019 Q1 | 6.36 Million SEK | 57.94% |
| 2019 FY | 12.41 Million SEK | 208.01% |
| 2019 Q4 | 12.41 Million SEK | -6.09% |
| 2019 Q3 | 13.21 Million SEK | -15.59% |
| 2018 Q2 | 4 Million SEK | 85.28% |
| 2018 FY | 4.03 Million SEK | 209.74% |
| 2018 Q4 | 4.03 Million SEK | 30.25% |
| 2018 Q3 | 3.09 Million SEK | -22.73% |
| 2018 Q1 | 2.16 Million SEK | 66.09% |
| 2017 Q3 | 1.81 Million SEK | 35.24% |
| 2017 Q1 | 986.45 Thousand SEK | -85.19% |
| 2017 Q2 | 1.34 Million SEK | 35.96% |
| 2017 Q4 | 1.3 Million SEK | -28.27% |
| 2017 FY | 1.3 Million SEK | -80.46% |
| 2016 Q1 | 742.15 Thousand SEK | -28.35% |
| 2016 FY | 6.65 Million SEK | 542.83% |
| 2016 Q3 | 1.01 Million SEK | -6.35% |
| 2016 Q4 | 6.65 Million SEK | 556.13% |
| 2016 Q2 | 1.08 Million SEK | 46.01% |
| 2015 Q3 | 2.6 Million SEK | -71.08% |
| 2015 Q4 | 1.03 Million SEK | -60.2% |
| 2015 Q1 | 4.68 Million SEK | 0.41% |
| 2015 Q2 | 8.99 Million SEK | 92.15% |
| 2015 FY | 1.03 Million SEK | -88.04% |
| 2014 FY | 8.66 Million SEK | 269.23% |
| 2014 Q4 | 4.66 Million SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2013 FY | 2.34 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -36.161% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.44% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.44% |
| Arcoma AB | 33.3 Million SEK | 55.037% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 95.458% |
| BICO Group AB (publ) | 3.26 Billion SEK | 99.541% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 94.65% |
| CellaVision AB (publ) | 212.32 Million SEK | 92.947% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -5.48% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -118.01% |
| C-Rad AB (publ) | 122.4 Million SEK | 87.766% |
| Duearity AB (publ) | 17.53 Million SEK | 14.575% |
| Dignitana AB (publ) | 37.56 Million SEK | 60.138% |
| Episurf Medical AB (publ) | 19.8 Million SEK | 24.369% |
| Getinge AB (publ) | 24.69 Billion SEK | 99.939% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | 27.307% |
| Iconovo AB (publ) | 14.55 Million SEK | -2.893% |
| Integrum AB (publ) | 22.07 Million SEK | 32.157% |
| Luxbright AB (publ) | 7 Million SEK | -113.925% |
| Mentice AB (publ) | 163.55 Million SEK | 90.844% |
| OssDsign AB (publ) | 105.25 Million SEK | 85.773% |
| Paxman AB (publ) | 44.5 Million SEK | 66.355% |
| Promimic AB (publ) | 16.15 Million SEK | 7.31% |
| Qlife Holding AB (publ) | 62.16 Million SEK | 75.912% |
| SciBase Holding AB (publ) | 21.27 Million SEK | 29.622% |
| ScandiDos AB (publ) | 37.18 Million SEK | 59.729% |
| Sectra AB (publ) | 1.64 Billion SEK | 99.088% |
| Sedana Medical AB (publ) | 44.06 Million SEK | 66.014% |
| Senzime AB (publ) | 58.06 Million SEK | 74.21% |
| Stille AB | 172.64 Million SEK | 91.326% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 99.592% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | 94.024% |